Calcium channel blockers and β-blockers in relation to Parkinson's disease

Parkinsonism and Related Disorders

Volumn 13, Issue 3, 2007, Pages 165-169

  Ton, Thanh G N ^a   Heckbert, Susan R ^a   Longstreth Jr , W T ^a   Rossing, Mary Anne ^a,b   Kukull, Walter A ^a   Franklin, Gary M ^a   Swanson, Phillip D ^a   Smith Weller, Terri ^a   Checkoway, Harvey ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

blockers; Calcium channel blockers; Case control; Epidemiology; Parkinson's disease

Indexed keywords

AMLODIPINE; ATENOLOL; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DILTIAZEM; FELODIPINE; LABETALOL; METOPROLOL; NADOLOL; NICARDIPINE; NIFEDIPINE; PROPRANOLOL; PROPRANOLOL DERIVATIVE; VERAPAMIL;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; COMMUNITY HEALTH PLANNING; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; RETROSPECTIVE STUDIES; RISK; TIME FACTORS;

EID: 33947245105     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2006.08.011     Document Type: Article

References (20)

1. Paganini-Hill A. Risk factors for parkinson's disease: the leisure world cohort study. Neuroepidemiology 20 (2001) 118-124
2. McCann S.J., LeCouteur D.G., Green A.C., Brayne C., Johnson A.G., Chan D., et al. The epidemiology of Parkinson's disease in an Australian population. Neuroepidemiology 17 (1998) 310-317
3. Fitzpatrick A.L., Daling J.R., Furberg C.D., Kronmal R.A., and Weissfeld J.L. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 80 (1997) 1438-1447
4. Pahor M., Guralnik J.M., Ferrucci L., Corti M.C., Salive M.E., Cerhan J.R., et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348 (1996) 493-497
5. Pahor M., Guralnik J.M., Salive M.E., Corti M.C., Carbonin P., and Havlik R.J. Do calcium channel blockers increase the risk of cancer?. Am J Hypertens 9 (1996) 695-699
6. Jick H., Madsen S., Nudelman P.M., Perera D.R., and Stergachis A. Postmarketing follow-up at group health cooperative of puget sound. Pharmacotherapy 4 (1984) 99-100
7. Rodnitzky R.L. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease?. Drugs 57 (1999) 845-849
8. 2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J Neurochem 62 (1994) 372-375
9. Kupsch A., Sautter J., Schwarz J., Riederer P., Gerlach M., and Oertel W.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 741 (1996) 185-196
10. Kupsch A., Gerlach M., Pupeter S.C., Sautter J., Dirr A., Arnold G., et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport 6 (1995) 621-625
11. Daniel J.R., and Mauro V.F. Extrapyramidal symptoms associated with calcium-channel blockers. Ann Pharmacother 29 (1995) 73-75
12. Bing G., Zhang Y., Watanabe Y., McEwen B.S., and Stone E.A. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 668 (1994) 261-265
13. Soldani P., and Fornai F. The functional anatomy of noradrenergic neurons in Parkinson's disease. Funct Neurol 14 (1999) 97-109
14. Gaspar P., Duyckaerts C., Alvarez C., Javoy-Agid F., and Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann Neurol 30 (1991) 365-374
15. Checkoway H., Powers K., Smith-Weller T., Franklin G.M., Longstreth Jr. W.T., and Swanson P.D. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 155 (2002) 732-738
16. Wickersham RM, Novak KK, editors. Drug Facts and comparisons. St. Louis, MO: Wolters Kluwer Health; 2005.
17. Hartley A., Stone J.M., Heron C., Cooper J.M., and Schapira A.H. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 63 (1994) 1987-1990
18. Powers K.M., Smith-Weller T., Franklin G.M., Longstreth Jr. W.T., Swanson P.D., and Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 12 3 (2006) 185-189
19. Garcia-Albea E., Jimenez-Jimenez F.J., Ayuso-Peralta L., Cabrera-Valdivia F., Vaquero A., and Tejeiro J. Parkinsonism unmasked by verapamil. Clin Neuropharmacol 16 (1993) 263-265
20. Saunders K.W., Stergachis A., and Von Korff M. Group health cooperative of puget sound. In: Strom B. (Ed). Pharmacoepidemiology (1994), Wiley, West Sussex 171-185